NEUROENDOCRINE TUMOR G2
Clinical trials for NEUROENDOCRINE TUMOR G2 explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE TUMOR G2 trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE TUMOR G2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in slowing rare carcinoid tumors
Disease control OngoingThis study tested a drug called pazopanib in 171 people with carcinoid tumors that were growing or spreading. The goal was to see if pazopanib could slow tumor growth better than a placebo. Participants were randomly assigned to receive either pazopanib or a placebo, and research…
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in slowing advanced neuroendocrine tumors
Disease control OngoingThis study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Major trial pits two drug cocktails against Hard-to-Treat cancers
Disease control OngoingThis study compares two drug combinations for people with advanced neuroendocrine tumors (carcinoid cancer) that cannot be removed by surgery. Participants receive either octreotide plus interferon or octreotide plus bevacizumab. The goal is to see which combination better slows …
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC